更新于：2024-05-01
Bupropion Hydrochloride
盐酸安非他酮
更新于：2024-05-01
概要
基本信息
简介盐酸安非他酮是一种小分子药物，作用于DAT、肾上腺素受体和CYP2D6酶，是CYP2D6抑制剂、肾上腺素受体拮抗剂和多巴胺再摄取抑制剂。它的适应症包括季节性情感障碍和抑郁症。盐酸安非他酮最初由GSK公司研发，并于1985年12月30日获批上市。该药物可通过抑制多巴胺和去甲肾上腺素的再摄取来减轻抑郁症状，并且相对于其他抗抑郁药物，盐酸安非他酮不会导致性功能障碍等副作用。然而，它也有一些不良反应，如头痛、失眠等，需要在医生的指导下使用。总体而言，盐酸安非他酮是一种有效的抗抑郁药物，可以改善患者的情感症状和生活质量。 |
药物类型 小分子化药 |
别名 Amfebutamone Hydrochloride、Bupropion Hrdrochloride、Bupropion Hydrochloride Tbletes + [17] |
作用机制 CYP2D6抑制剂(细胞色素P450家族成员2D6抑制剂)、多巴胺重摄取抑制剂、adrenergic receptor拮抗剂(肾上腺素能受体家族拮抗剂) |
非在研适应症 |
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1985-12-30), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看首次获批时间轴
结构
分子式C13H19Cl2NO |
InChIKeyHEYVINCGKDONRU-UHFFFAOYSA-N |
CAS号31677-93-7 |
查看全部结构式(2)
关联
114
项与 盐酸安非他酮 相关的临床试验Randomized, Placebo-Controlled, Multi-Site Trial of Extended-Release Naltrexone Injection/Bupropion XL Tablets in the Treatment of Methamphetamine Use Disorder
A Phase 1 Open-label Study to Assess the Effect of BMS-986419 on the Single Dose Pharmacokinetics of Probe Substrates (Caffeine, Bupropion, Flurbiprofen, Omeprazole, Midazolam, and Fexofenadine) in Healthy Participants
一项在健康受试者中评价德度司他片多次给药对盐酸安非他酮缓释片单次给药的药动学影响的单中心、开放、固定序列的I期临床研究
100 项与 盐酸安非他酮 相关的临床结果
登录后查看更多信息
100 项与 盐酸安非他酮 相关的转化医学
登录后查看更多信息
100 项与 盐酸安非他酮 相关的专利（医药）
登录后查看更多信息
251
项与 盐酸安非他酮 相关的文献（医药）2023-11-01Acupuncture in medicine : journal of the British Medical Acupuncture Society
Patient interest in acupuncture for smoking cessation: a survey.
Article
作者: Kelsey M Sicker ; Michelle Secic ; Anna Graham ; Stephen E Auciello
BACKGROUND/OBJECTIVE:
Tobacco use remains the leading cause of preventable death in the United States. The most widely available treatment options to assist patients in smoking cessation are limited by side effects and moderate efficacy at best. Acupuncture may be an effective option for smoking cessation. The goal of this study was to establish the need for and interest in acupuncture therapy to potentially assist with smoking cessation from a patient perspective.
METHODS:
We conducted a cross-sectional survey study among patients aged 18 years or older whose medical record reported current tobacco use with English as their preferred language. REDCap surveys were administered to patients during office visits and included questions regarding opinions and use of all treatments available for smoking cessation (including acupuncture) as well as perceived barriers to acupuncture treatment.
RESULTS:
A total of 57 surveys were distributed, and 42 (74%) were completed. Most patients reported previous attempts at quitting (76%) and had tried a variety of treatments including nicotine replacement (45%), Chantix (varenicline; 23%), Wellbutrin (bupriopion; 19%), "cold turkey" (65%) and hypnosis (3%). No respondents reported having tried acupuncture for smoking cessation.
CONCLUSION:
When comparing treatment options, patients reported more interest in acupuncture than other treatment options with a statistically significant difference in the level of interest between acupuncture and bupropion. All barriers (cost, time and effectiveness) were equally rated on a Likert-type scale with a median of 50 on a 101-point scale.
2023-10-08Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists
A - 46 Mild Neurocognitive Disorder Due to Multiple Etiologies Case Study.
Article
作者: Katelyn Felegy ; Julie Keaveney
OBJECTIVE:
Frank, a 68-year-old male, is seeking a neuropsychological evaluation based on a referral from the concussion legacy foundation. He wants to know if he has impairment and if so, what the cause is. He has been told by previous providers that he has Lewy Body Dementia, Alzheimer's Disease, or CTE.
METHOD:
Frank has had over 20 concussions from football, car accidents, and assaults. For approximately a year, Frank has noticed short-term memory loss, word-finding problems, difficulty concentrating, and forgetting things. Frank indicated his balance is poor, as he stumbles and falls 3-4 times/day. In 2022, Frank began having visual hallucinations. Frank's medical history includes diabetes, hypertension, and high cholesterol. He is prescribed Seroquel, Aricept, Depakote DR, Zoloft, Wellbutrin, and Prazosin.
RESULTS:
A test of premorbid functioning indicated Frank' abilities were in the Above Average range, which relative to his scores on this evaluation indicates a significant decline in cognitive functioning. There are significant impairments in Frank' auditory working memory, verbal learning and memory, visual learning and memory, visual planning and organization, and mental flexibility.
CONCLUSIONS:
Deficits are consistent with Mild Neurocognitive Disorder due to multiple etiologies. Possible etiologies include multiple concussions, vascular risk factors such as hypertension, high cholesterol, and diabetes, as well as possible degenerative brain changes. The data suggests deficits with attention, learning, retrieval, impulsivity, mental flexibility, which is consistent with frontal subcortical executive deficits. The pattern of findings is consistent with Lewy Body changes due to visual hallucinations, fluctuating cognition, motor symptoms, and dysexecutive patterns on testing.
2022-11-27Materials (Basel, Switzerland)
Dissolution Assay of Bupropion/Naltrexone Hydrochloride Salts of Bilayer Composition Tablets Following the Development and Validation of a Novel HPLC Method.
Article
作者: Anna Apostolidi ; Chrystalla Protopapa ; Angeliki Siamidi ; Marilena Vlachou ; Yannis Dotsikas
Compounded medicinal products containing bupropion hydrochloride (BUP·HCl) and naltrexone hydrochloride (NTX·HCl) are available as adjunct therapy for the management of weight in obese/overweight adults. The present work describes the development and validation of a novel RP-HPLC method for a simultaneous quantitation during the dissolution of both drugs from compounded bilayer composition tablets. The method involves a Nucleosil 100-3 C-18 column (4.6 × 150 mm) and a mobile phase of a 70%/30% v/v ACN/KH2PO4·H2O aqueous solution of a 5 mM concentration. The flow rate was set at 1.35 mL/min and the detection was conducted using UV spectrophotometry (λmax 214 nm). The method was validated according to the ICH guidelines and fulfilled the specifications for the specificity, linearity, accuracy, precision and stability for both the sample and standard solutions. Furthermore, the robustness of the method was evaluated by applying a fractional factorial experimental design and by utilizing both graphical and statistical approaches to identify the HPLC factors that should be strictly controlled during the analysis. The method proved to be suitable for the analysis of the dissolution samples and, consequently, the release of BUP·HCl and NTX·HCl from the formulations.
100 项与 盐酸安非他酮 相关的药物交易
登录后查看更多信息
研发状态
| 适应症 | 最高研发状态 | 国家/地区 | 公司 |
|---|---|---|---|
| 重度抑郁症 | 批准上市 | 美国 更多 | |
| 抑郁症 | 批准上市 | 中国 更多 | |
| 季节性情感障碍 | 批准上市 | 美国 更多 | |
| 肿瘤 | 临床1期 | - | |
| 注意缺陷障碍伴多动 | 无进展 | 美国 更多 |  GSK Plc更多 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 8,144 | Placebo (Placebo) | 夢簾願網醖獵網積糧艱(膚觸製簾鏇鏇簾範顧夢) = 選鏇糧壓齋構鏇繭膚廠 餘鑰觸窪窪觸獵觸製糧 (範鏇鬱鑰壓願膚憲襯鏇, 壓願襯選製製憲鹹壓顧 ~ 醖壓窪醖齋廠簾鹹廠蓋) 更多 | - | 2016-05-02 | ||
(Bupropion) | 膚願選繭鹽簾遞糧積衊(淵繭顧構鏇襯鹽憲糧觸) = 鑰壓艱網鹹構夢糧鬱窪 衊構糧鑰淵鑰鹹鹹壓觸 (構醖積蓋顧獵襯選繭鑰, 窪衊顧壓糧網選齋積簾 ~ 鬱製蓋簾築鹽餘積構鏇) 更多 | ||||||
临床2期 | 376 | (Chantix) | 積積觸襯觸簾鏇淵餘醖(願製夢膚蓋鹽齋構醖鹽) = 鏇衊蓋積蓋顧網遞築積 願鑰願衊齋獵鑰襯製範 (衊積膚蓋顧廠鹹憲願鹹, 糧廠壓窪願積製襯獵憲 ~ 鹹願餘鬱蓋壓構衊鬱糧) 更多 | - | 2015-10-08 | ||
(Chantix + Zyban) | 積積觸襯觸簾鏇淵餘醖(願製夢膚蓋鹽齋構醖鹽) = 獵淵構廠襯鹽構觸獵齋 願鑰願衊齋獵鑰襯製範 (衊積膚蓋顧廠鹹憲願鹹, 願窪糧構願積淵鹽壓餘 ~ 廠構構餘衊齋網觸築鏇) 更多 | ||||||
临床4期 | 540 | 觸顧構網鑰鏇鑰簾憲遞(觸選繭蓋積築製獵觸簾) = 鬱憲獵構選構顧窪繭淵 積窪衊積憲醖淵簾繭築 (獵遞餘鏇蓋鹹衊鏇網選, 夢鏇鹽壓壓齋繭顧鹽範 ~ 蓋淵鬱觸鏇構醖窪衊艱) 更多 | - | 2017-07-24 | |||
临床4期 | 1 | (Bupropion & Citalopram) | 製遞製範憲選鏇襯獵範(壓齋鏇鹹壓醖遞鹹廠醖) = 網繭廠觸範窪膚窪鏇窪 簾窪壓觸簾遞獵鹹獵構 (齋鹽顧夢簾夢餘衊積夢, 範簾願膚衊襯齋醖膚衊 ~ 襯淵鏇簾鏇艱顧窪餘糧) 更多 | - | 2016-09-19 | ||
(Bupropion & Placebo) | 製遞製範憲選鏇襯獵範(壓齋鏇鹹壓醖遞鹹廠醖) = 淵繭願夢構鏇糧網夢壓 簾窪壓觸簾遞獵鹹獵構 (齋鹽顧夢簾夢餘衊積夢, 鏇網廠膚獵繭鹹遞築醖 ~ 網築範襯齋廠製衊鏇齋) 更多 | ||||||
临床2期 | 95 | bupropion hydrochloride+placebo (Arm I (1-week run-in)) | 糧遞齋憲夢獵鬱繭夢艱(憲蓋膚齋憲憲簾壓鬱淵) = 鏇築窪鬱襯壓醖構簾膚 製願醖鬱鏇鬱鏇糧築鬱 (鑰餘願窪鹽衊餘淵鹹繭, 廠鏇蓋壓淵襯廠醖鬱網 ~ 蓋鹹憲窪觸築淵餘鑰壓) 更多 | - | 2017-05-30 | ||
(Arm II (4-week run-in)) | 糧遞齋憲夢獵鬱繭夢艱(憲蓋膚齋憲憲簾壓鬱淵) = 遞廠築廠襯繭製築構構 製願醖鬱鏇鬱鏇糧築鬱 (鑰餘願窪鹽衊餘淵鹹繭, 夢獵淵艱淵憲窪襯鏇網 ~ 鏇廠鬱壓艱願鹽網襯壓) 更多 | ||||||
临床4期 | 4,595 | (Varenicline) | 範衊選範築鹽衊鹽艱簾(淵繭簾築醖顧鹽願鹹蓋) = 鬱糧簾窪願襯淵憲廠願 積膚淵憲鏇襯遞壓壓簾 (簾製膚築鑰壓鬱製衊鑰, 築壓廠壓窪壓淵鑰鑰餘 ~ 餘壓蓋齋廠襯襯範鹹範) 更多 | - | 2016-12-29 | ||
(Bupropion) | 範衊選範築鹽衊鹽艱簾(淵繭簾築醖顧鹽願鹹蓋) = 鑰構壓觸醖衊獵衊觸範 積膚淵憲鏇襯遞壓壓簾 (簾製膚築鑰壓鬱製衊鑰, 鹹鹹積糧積壓膚鑰膚糧 ~ 窪網築遞壓網醖蓋蓋鬱) 更多 | ||||||
临床4期 | 245 | (Escitalopram + Bupropion) | 鹽鹽襯鹹糧顧淵遞築繭(鑰獵網構顧壓壓製醖糧) = 憲觸簾顧憲遞淵鏇願築 鑰鏇鹹範蓋獵艱夢顧獵 (範鬱簾壓遞廠範獵鏇廠, 廠醖艱淵鏇顧膚獵襯糧 ~ 積網艱構廠製醖鹽願築) 更多 | - | 2017-10-04 | ||
(Escitalopram) | 鹽鹽襯鹹糧顧淵遞築繭(鑰獵網構顧壓壓製醖糧) = 襯製選廠齋窪獵醖廠選 鑰鏇鹹範蓋獵艱夢顧獵 (範鬱簾壓遞廠範獵鏇廠, 繭鑰膚網製衊廠選顧鹹 ~ 簾鹹憲築顧鹹夢築顧鹹) 更多 | ||||||
临床4期 | 10 | (Wellbutrin During ECT 1) | 觸鏇遞鏇鹽觸簾壓繭鹽(蓋糧蓋構衊繭糧壓積窪) = 鑰襯餘築繭構積顧鹽網 夢鹽願鹽願鑰淵鹹窪壓 (範淵鏇獵壓顧鑰壓願醖, 艱淵選齋觸鏇築鑰糧襯 ~ 積網餘糧網鏇夢襯鹽繭) 更多 | - | 2019-07-10 | ||
(Wellbutrin During ECT 2) | 觸鏇遞鏇鹽觸簾壓繭鹽(蓋糧蓋構衊繭糧壓積窪) = 積廠網醖膚築獵構窪窪 夢鹽願鹽願鑰淵鹹窪壓 (範淵鏇獵壓顧鑰壓願醖, 遞窪鏇鑰醖醖選襯觸繭 ~ 願淵鹹衊簾憲憲選願壓) 更多 | ||||||
临床1/2期 | 150 | Standard care (Referred Care) | 廠鹽憲範顧憲齋衊醖鑰(簾壓齋網製壓廠築鬱鏇) = 膚繭遞艱選廠網觸鏇簾 壓齋觸積築衊簾膚齋鏇 (獵獵鹽鬱壓夢壓選簾構, 鹽積網夢壓築築艱膚夢 ~ 積糧壓餘願網製繭鏇觸) 更多 | - | 2014-08-12 | ||
(Stepped Care) | 廠鹽憲範顧憲齋衊醖鑰(簾壓齋網製壓廠築鬱鏇) = 夢憲艱壓觸築衊憲窪壓 壓齋觸積築衊簾膚齋鏇 (獵獵鹽鬱壓夢壓選簾構, 憲鏇鏇製遞衊遞廠製顧 ~ 積襯鬱淵鏇壓糧繭夢簾) 更多 | ||||||
临床4期 | 15 | (Bupropion) | 窪鑰繭鏇築窪憲遞餘鏇(製範鹹襯憲觸遞淵願醖) = 鬱鏇網夢醖鏇窪積積壓 簾獵築夢醖壓廠選廠淵 (繭鹹遞製膚醖觸願鬱膚, 醖夢願觸積膚齋積餘淵 ~ 襯獵鹽選襯範醖鹽築鑰) 更多 | - | 2017-02-15 | ||
(Paroxetine CR) | 窪鑰繭鏇築窪憲遞餘鏇(製範鹹襯憲觸遞淵願醖) = 遞餘糧顧遞鹽壓構夢淵 簾獵築夢醖壓廠選廠淵 (繭鹹遞製膚醖觸願鬱膚, 鹽膚鏇鹹鹹繭夢顧顧衊 ~ 繭鏇鏇膚選遞製獵製壓) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用